Diligence memo · auto-generated · as of July 2, 2026
Nido Biosciences, Inc.
Nido Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Nido Biosciences, Inc. operates in Biotech / Pharma, based in Cambridge.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nido Biosciences, Inc. has raised $22M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2020-08-24.
Most recent recorded round closed around 2020-08-24.
Valuation (modeled)modeled
Provath models Nido Biosciences, Inc. at approximately $637M (range $38M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.24× the median modeled value of Series B Biotech / Pharma companies in 2019–2021 (11 peers) — value vs value, same stage and era. Within the normal band (124% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 5.9 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 78% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Mantra Bio, Inc., Front Range Biosciences, Inc., LifeVault Bio, Inc., Pharmajet, Inc., Paragon Biosciences CIRC Holdings, LLC.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.